Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiawei Xiaolong pill is a traditional Chinese medicine (TCM) formulation developed by Longhua Hospital affiliated with the Shanghai University of Traditional Chinese Medicine in collaboration with the Shanghai Shenkang Hospital Development Center. It is administered orally and is currently being investigated for its potential to reduce the risk of malignancy in patients with residual lung ground glass nodules (GGN). The therapeutic approach is based on TCM principles, often involving the regulation of 'Qi' and the resolution of phlegm or stasis, though specific molecular targets have not been publicly characterized. The clinical evaluation of this drug incorporates AI image judgment technology to monitor changes in nodule characteristics and assess the risk of malignant transformation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jiawei Xiaolong pill.